BLAINJECTIONINJECTABLE
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
OGIVRI (trastuzumab-dkst) by Viatris is her2/neu/cerbb2 antagonists [moa]. First approved in 2017.
Drug data last refreshed 9h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OGIVRI (trastuzumab-dkst) is a biosimilar monoclonal antibody that targets HER2/neu receptors, used to treat HER2-positive cancers by blocking tumor cell growth signals. It is a follow-on biologic to Herceptin approved via the 351(k) BLA pathway in December 2017. The drug works by binding to HER2 receptors on cancer cells, preventing their proliferation and triggering immune-mediated cell death.
$0.822MPart D
PeakOGIVRI is in peak lifecycle with modest Part D engagement; commercial teams should anticipate competitive pressure intensification as biosimilar adoption increases in oncology.
Mechanism of Action
HER2/Neu/cerbB2 Antagonists
Pharmacologic Class:
HER2/neu Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Viatris is hiring 1 role related to this product
Worked on OGIVRI at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.